CSF Acetylated Tau‐174 as a novel diagnostic and prognostic biomarker in Frontotemporal Dementia and Alzheimer’s Disease
CSF AcTau174 shows great diagnostic value across neurodegenerative dementias and is strongly associated with clinical progression. In FTD, where trials are limited by clinical heterogeneity and lack of fluid biomarkers, AcTau174 may aid in identifying patients at risk of rapid decline, supporting trial enrichment and more targeted intervention strategies. Its predictive capacity for MMSE decline highlights its potential as a progression biomarker, both for patient monitoring and therapeutic development.
Authors
- Flora H. Duits
- C. Teunissen
- Elisabeth H. Thijssen (ORCID: https://orcid.org/0000-0002-9723-5441)
- Emma L. van der Ende (ORCID: https://orcid.org/0000-0003-2570-8796)
- Yolande A.L. Pijnenburg (ORCID: https://orcid.org/0000-0003-2464-1905)
- Sterre CM. de Boer
- Li Gan
- Inge M.W. Verberk
- Yanaika S. Hok‐A‐Hin
- Babette van der Weijden
- Erik Stoops
- Wiesje M. van der Flier
- Madison I. J. Honey
Institutions
- Ablynx (Belgium) (BE)
- Cornell University (US)
- MIND Research Institute (US)
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- ADx NeuroSciences
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108639
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00